Reardon Andrew

CLO & SecretaryLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed May 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
9
8 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)5K$52.27$261K46K
May 1, 2026Sell(S)600$227.45$136K46K
May 1, 2026Sell(S)932$228.75$213K45K
May 1, 2026Sell(S)98$229.71$23K45K
May 1, 2026Sell(S)370$230.87$85K44K
May 1, 2026Sell(S)780$232.04$181K44K
May 1, 2026Sell(S)1K$232.92$331K42K
May 1, 2026Sell(S)800$234.02$187K41K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)5K$044K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000046) within minutes of acceptance. Every field above traces to the original document. Verify it directly: